{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T21:31:00Z","timestamp":1779139860383,"version":"3.51.4"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The global prevalence of poor anticoagulation control with warfarin therapy is high. Similarly, the quality of anticoagulation control with warfarin therapy in Ethiopia has been reported to be poor, with a notable paucity of data, especially in the western part of the country.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study aimed to evaluate the anticoagulation quality, and associated factors among adult outpatients on warfarin therapy at Wallaga University Referral Hospital and Nekemte Comprehensive Specialized Hospital, Nekemte town, Western Ethiopia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective study was conducted at public hospitals in Nekemte town from June 1 to 31 July 2023. Data were collected by reviewing patients\u2019 medical charts using a systematic random sampling technique. Time in the therapeutic range was determined using the Rosendaal method. The collected data were entered into EpiData version 4.6.0 and then exported to SPSS version 27.0 for analysis. Bivariable and multivariable logistic regression analyses were performed to identify significant associations. In the multivariable analysis, statistical significance was declared at a p-value of less than 0.05.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 402 patient medical charts with warfarin indications were reviewed. The mean age of the study participants was 38.9 \u00b1 17.9\u00a0years, and 271 (67.4%) were female. Good warfarin anticoagulation quality was observed in 36 (9%) of the patients. Aspirin use (AOR = 2.685; CI: 0.872\u201310.277; p-value = 0.002) and congestive heart failure (AOR = 4.392; CI: 1.028\u201318.768; p-value = 0.046) were identified as independent predictors of poor anticoagulation quality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Aspirin use and congestive heart failure were independent predictors of poor anticoagulation quality with warfarin therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1544957","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T08:33:45Z","timestamp":1743669225000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Anticoagulation quality with warfarin therapy, and associated factors among adult outpatients at public hospitals in nekemte town, western Ethiopia: a retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Firafan Shuma","family":"Teka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayana Tadesse","family":"Korsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habte","family":"Gebeyehu Bayisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dechasa","family":"Befikadu W\/Senbat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Refisa","family":"Shifera Beyene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinka","family":"Dugassa Iticha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birbirsa","family":"Sefera Senbeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"B2","article-title":"Warfarin anticoagulation practice in Ethiopian hospitals: exploring clinical practice, knowledge, and perceptions","volume":"15","author":"Abegaz","year":"2020","journal-title":"PLoS One"},{"key":"B3","first-page":"43","article-title":"Anticoagulation therapy control among patients in Ethiopia: a systematic review and meta-analysis","volume":"20","author":"Alemu","year":"2022","journal-title":"Thromb. J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2147\/RMHP.S248222","article-title":"Anticoagulation control of warfarin in pharmacist-led clinics versus physician-led clinics: a prospective observational study","volume":"13","author":"Alghadeeer","year":"2020","journal-title":"Risk Manag. Healthc. Policy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2152\/jmi.64.266","article-title":"Hospital pharmacist intervention improves the quality indicator of warfarin control: a retrospective cohort study","volume":"64","author":"An","year":"2017","journal-title":"J. Med. Investig."},{"key":"B6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.5543\/tkda.2021.21015","article-title":"Time in therapeutic range values of patients using warfarin and factors that influence time in therapeutic range","volume":"49","author":"Asarc\u0131kl\u0131","year":"2021","journal-title":"Turk Kardiyol. Dern. Ars"},{"key":"B7","first-page":"241","volume-title":"Optimization of monitoring and management of anticoagulant therapy","author":"Biedermann","year":"2017"},{"key":"B8","first-page":"504","volume-title":"Short communication impact of aspirin on warfarin control as measured by time in therapeutic range","author":"Boyce","year":"2018"},{"key":"B9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.5114\/kitp.2015.56784","article-title":"Factors affecting the quality of anticoagulation with warfarin: experience of one cardiac centre","volume":"12","author":"Ciurus","year":"2015","journal-title":"Kardiochirurgia i Torakochirurgia Pol."},{"key":"B10","first-page":"110","article-title":"Drug interactions and adverse events in a cohort of warfarin users attending public health clinics","volume":"32","author":"Colet","year":"2018","journal-title":"Int. J. Cardiovasc Sci."},{"key":"B11","article-title":"Warfarin time in therapeutic INR range and direct oral anticoagulant adherence for venous thromboembolism across the spectrum of weight and body mass index","volume-title":"Findings from veterans health administration","author":"Din","year":"2023"},{"key":"B12","doi-asserted-by":"publisher","first-page":"490","DOI":"10.7196\/SAMJ.2018.v108i6.13062","article-title":"Poor anticoagulation control in patients taking warfarin at a tertiary and district-level prothrombin clinic in Cape Town, South Africa","volume":"108","author":"Ebrahim","year":"2018","journal-title":"South Afr. Med. J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bcp.14428","article-title":"Drug-drug interaction between warfarin and statins: a Danish cohort study","volume":"87","author":"Engell","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-017-2330-0","article-title":"Quality of anticoagulation management with warfarin among outpatients in a tertiary hospital in Addis Ababa, Ethiopia: a retrospective cross-sectional study","volume":"17","author":"Fenta","year":"2017","journal-title":"BMC Health Serv. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.thromres.2015.06.007","article-title":"Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink","volume":"136","author":"Filipa","year":"2015","journal-title":"Thromb. Res."},{"key":"B16","first-page":"275","article-title":"A. Practical management of bleeding due to warfarin and other anticoagulants","volume":"132","author":"Garcia","year":"2019","journal-title":"Am. J. Med."},{"key":"B17","first-page":"425","article-title":"Time in therapeutic range Un RIN dans la fourchette th\u00e9rapeutique;Time in therapeutic range: Warfarin anticoagulation for atrial fibrillation in a community-based practice","volume":"63","author":"Gateman","year":"2017","journal-title":"Can. Fam. Physician"},{"key":"B18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/JBM.S397189","article-title":"Anticoagulation management in patients receiving warfarin at private cardiac centers in Addis Ababa, Ethiopia","volume":"14","author":"Getachew","year":"2023","journal-title":"J. Blood Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0164076","DOI":"10.1371\/journal.pone.0164076","article-title":"Quality of vitamin K antagonist control and 1- year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD- AF registry","volume":"11","author":"Haas","year":"2016","journal-title":"PLoS One"},{"key":"B21","first-page":"1339","article-title":"Evaluation of quality of warfarin therapy by assessing patient\u2019s time in therapeutic range at a tertiary care hospital in Pakistan","volume":"68","author":"Hakem","year":"2018","journal-title":"J. Pak Med. Assoc."},{"key":"B22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medicina55010015","article-title":"The quality of anticoagulation therapy among warfarin-treated patients with atrial fibrillation in a primary health care setting","volume":"55","author":"Health","year":"2019","journal-title":"Med"},{"key":"B23","first-page":"1","article-title":"Guidelines for warfarin management in the community Guidelines for Warfarin Management in the Community Guidelines for warfarin management in the community -iii","author":"Health","year":"2016","journal-title":"Dep. Heal"},{"key":"B24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur. Heart J."},{"key":"B25","first-page":"65","article-title":"Global trends in time in therapeutic range among warfarin users","volume":"219","author":"Jones","year":"2022","journal-title":"Thromb. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/VHRM.S347667","article-title":"Magnitudes of risk factors of venous thromboembolism and quality of anticoagulant therapy in Ethiopia: a systematic review","volume":"18","author":"Kebede","year":"2022","journal-title":"A Syst. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.7196\/SAMJ.2018.v108i12.13256","article-title":"An evaluation of warfarin use at an urban district-level hospital in KwaZulu-Natal Province, South Africa","volume":"108","author":"La\u00e4s","year":"2018"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-020-01600-z","article-title":"Time in therapeutic range, quality of life and treatment satisfaction of patients on long - term warfarin for non - valvular atrial fibrillation: a cross - sectional study","author":"Leh","year":"2020","journal-title":"Health Qual. Life Outcomes"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.2147\/PPA.S204246","article-title":"Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study","volume":"13","author":"Leh-Ching Ng","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7530997","DOI":"10.1155\/2021\/7530997","article-title":"Evaluation of anticoagulation control among patients taking warfarin in university of gondar hospital, northwest Ethiopia","volume":"2021","author":"Liyew","year":"2021","journal-title":"Adv. Hematol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/JBM.S282948","article-title":"Evaluation of warfarin anticoagulation at university of gondar comprehensive specialized hospital, north-west Ethiopia","volume":"12","author":"Masresha","year":"2021","journal-title":"J. Blood Med."},{"key":"B33","first-page":"1475","volume-title":"Time in the therapeutic range for patients taking warfarin in clinical trials","author":"Misleading","year":"2017"},{"key":"B34","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/1076029617747413","article-title":"Quality of anticoagulation with warfarin at a tertiary hospital in Botswana","volume":"24","author":"Mwita","year":"2018","journal-title":"Clin. Appl. Thromb."},{"key":"B35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.amjcard.2013.04.013","article-title":"Impact of Co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation","volume":"112","author":"Nelson","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.hlc.2019.11.006","article-title":"Quality of warfarin anticoagulation in indigenous and non-indigenous Australians with atrial fibrillation","volume":"29","author":"Nguyen","year":"2020","journal-title":"Hear Lung Circ."},{"key":"B37","first-page":"1","volume-title":"Clinical Practice guideline for anticoagulation management","author":"Of","year":"2016"},{"key":"B38","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ijcard.2015.08.054","article-title":"Inadequate anticoagulation by vitamin K antagonists is associated with major adverse cardiovascular events in patients with atrial fibrillation","volume":"201","author":"Pastori","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"B39","first-page":"1234","article-title":"Anticoagulation strategies in atrial fibrillation and venous thromboembolism","volume":"7","author":"Patel","year":"2023","journal-title":"Blood Adv."},{"key":"B40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ahj.2015.03.017","article-title":"Patients \u2019 time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry","volume":"170","author":"Pokorney","year":"2015","journal-title":"Am. Heart J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"605353","DOI":"10.3389\/fphar.2020.605353","article-title":"Anticoagulation quality of warfarin and the role of physician\u2013pharmacist collaborative clinics in the treatment of patients receiving warfarin: a retrospective, observational, single-center study","volume":"11","author":"Qiu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B42","first-page":"112","article-title":"Warfarin therapy in heart failure patients: challenges and solutions","volume":"27","author":"Rodriguez","year":"2020","journal-title":"Cardiol. J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.rec.2014.11.019","article-title":"Quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors","volume":"68","author":"Sa","year":"2015","journal-title":"Rev. Esp. Cardiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"764","DOI":"10.5603\/KP.2018.0011","article-title":"Quality control of oral anticoagulation with Vitamin K antagonists in primary care patients in Poland: a multi-centre study","volume":"76","author":"Sawicka-Powierza","year":"2018","journal-title":"Kardiol. Pol."},{"key":"B45","first-page":"735","article-title":"How I monitor warfarin therapy","volume":"135","author":"Schulman","year":"2020","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1111\/bcp.14796","article-title":"Anticoagulation in sub-Saharan Africa: are direct oral anticoagulants the answer? A review of lessons learnt from warfarin","volume":"87","author":"Semakula","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B47","first-page":"1","volume-title":"A prospective study on the use of warfarin in the United Arab Emirates A prospective study on the use of warfarin in the United Arab Emirates","author":"Shehab","year":"2012"},{"key":"B48","first-page":"1238","article-title":"Warfarin monitoring and management: an updated review","volume":"19","author":"Smith","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"B49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12959-022-00416-9","article-title":"Anticoagulation control, outcomes, and associated factors in long-term-care patients receiving warfarin in Africa: a systematic review","volume":"20","author":"Tadesse","year":"2022","journal-title":"Thromb. J."},{"key":"B50","doi-asserted-by":"publisher","first-page":"10760296241277140","DOI":"10.1177\/10760296241277140","article-title":"Knowledge, adherence, and satisfaction with warfarin therapy and associated factors among outpatients at university teaching hospital in Ethiopia","volume":"30","author":"Tadesse","year":"2024","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2021.651799","article-title":"Low quality of warfarin therapy is associated with female gender but not with polypharmacy in patients with atrial fibrillation","volume":"12","author":"Takamoto","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B52","first-page":"1","volume-title":"ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) the Task Force for the diagnosis and management of atrial fibrillation of the Europea","author":"Task","year":"2020"},{"key":"B1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-9560-12-20","article-title":"Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: A prospective observational study","volume":"12","author":"Teklay","year":"2024","journal-title":"Thromb. J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"10760296211049786","DOI":"10.1177\/10760296211049786","article-title":"Anticoagulation control, outcomes, and associated factors in patients with atrial fibrillation receiving warfarin at tertiary care hospital in Ethiopia","volume":"27","author":"Yimer","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"B54","doi-asserted-by":"publisher","first-page":"925571","DOI":"10.3389\/fcvm.2022.925571","article-title":"Rosendaal linear interpolation method appraising of time in therapeutic range in patients with 12-week follow-up interval after mechanical heart valve replacement","volume":"9","author":"Zhu","year":"2022","journal-title":"Front. Cardiovasc Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1544957\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T08:35:15Z","timestamp":1743669315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1544957\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":52,"alternative-id":["10.3389\/fphar.2025.1544957"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1544957","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"article-number":"1544957"}}